Tracking Baker Brothers Portfolio – Q2 2018 Update

• Baker Brothers’ 13F portfolio value increased from $11.80B to $13.31B.
• BeiGene stake was doubled during the quarter.
• The top-three positions are Incyte Corporation, Seattle Genetics, and BeiGene and they add up to almost ~56% of the portfolio.

This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2018.

This quarter, Baker Brothers’ 13F portfolio increased ~13% from $11.80B to $13.31B. The top three holdings are at ~56% while the top five holdings are close to ~69% of the 13F assets: Incyte Corporation (INCY), Seattle Genetics (SGEN), BeiGene (BGNE), Alexion Pharmaceuticals (ALXN), and BioMarin Pharmaceuticals (BMRN).

The spreadsheet below highlights changes to Baker Brothers’ 13F holdings in Q2 2018. For a look at how the portfolio has progressed, please see our previous update:

To learn more about how to profit from a strategy of following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little Guy .